Relamine

**Relamine** was a U.S. oral prescription nutraceutical product developed and marketed by Zylera Pharmaceuticals for osteoarthritis. It combined chondroitin sulfate 300 mg, glucosamine 400 mg, and Primorine 425 mg per tablet. The product was intended to support articular-cartilage matrix maintenance and relieve osteoarthritis-associated pain and swelling; its glucosamine and chondroitin components provide cartilage-associated amino-sugar and glycosaminoglycan substrates, while Primorine was described as a carbonyl-trapping agent. Evidence for the specific three-ingredient combination was limited, with published commentary noting that the combination itself had not been clinically evaluated. Relamine was historically launched as a prescription product in the United States and is listed as discontinued. ([biospace.com](https://www.biospace.com/zylera-pharmaceuticals-announces-availability-of-relamine-for-the-treatment-of-osteoarthritis))

Brand names

Relamine

Other names

chondroitin + glucosamine + primorineglucosamine + chondroitin + primorineRe-lamine